Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS San Matteo Foundation, 27100 Pavia, Italy.
Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, School of Medicine, University of Pavia, 27100 Pavia, Italy.
Cells. 2022 Apr 15;11(8):1355. doi: 10.3390/cells11081355.
Migraine is a major neurological disorder affecting one in nine adults worldwide with a significant impact on health care and socioeconomic systems. Migraine is more prevalent in women than in men, with 17% of all women meeting the diagnostic criteria for migraine. In women, the frequency of migraine attacks shows variations over the menstrual cycle and pregnancy, and the use of combined hormonal contraception (CHC) or hormone replacement therapy (HRT) can unveil or modify migraine disease. In the general population, 18-25% of female migraineurs display a menstrual association of their headache. Here we present an overview on the evidence supporting the role of reproductive hormones, in particular estrogens, in the pathophysiology of migraine. We also analyze the efficacy and safety of prescribing exogenous estrogens as a potential treatment for menstrual-related migraine. Finally, we point to controversial issues and future research areas in the field of reproductive hormones and migraine.
偏头痛是一种影响全球九分之一成年人的主要神经系统疾病,对医疗保健和社会经济系统有重大影响。偏头痛在女性中比男性更为常见,有 17%的女性符合偏头痛的诊断标准。在女性中,偏头痛发作的频率在月经周期和怀孕期间会发生变化,并且使用复方激素避孕药(CHC)或激素替代疗法(HRT)可能会引发或改变偏头痛疾病。在普通人群中,18-25%的女性偏头痛患者会出现头痛与月经相关。在这里,我们概述了支持生殖激素(特别是雌激素)在偏头痛病理生理学中的作用的证据。我们还分析了处方外源性雌激素作为治疗与月经相关的偏头痛的潜在疗法的疗效和安全性。最后,我们指出了生殖激素和偏头痛领域的争议问题和未来研究领域。